Clinical trials · San Francisco, CA
Cancer clinical trials in San Francisco
We’re tracking 483 recruiting cancer studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT06475989RecruitingPhase 3
Targeted Drug Combo vs. Chemo for Advanced Thyroid Cancer
This study tests a new combination of targeted drugs (dabrafenib and trametinib) compared to chemotherapy (cabozantinib) for people with a specific type of advanced thyroid cancer called BRAF-mutated differentiated thyroid cancer. The goal is to see which treatment works better.
Palo Alto, CaliforniaAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT03384238RecruitingPhase 1/Phase 2
Panitumumab dye during pancreatic surgery
This trial tests whether a targeted antibody with a fluorescent dye can help surgeons see and remove pancreatic cancer during planned surgery. It’s an early-phase study, so the main goal is to see if the approach is safe and useful around the time of the operation.
Palo Alto, CaliforniaAges 19 years+ - NCT05563766RecruitingPhase 2
Itraconazole added for treatable esophageal cancer before surgery
This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT05486572Recruiting
Ultrasound or MRI to help prevent liver cancer deaths
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
Palo Alto, CaliforniaAges 18–75 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Palo Alto, CaliforniaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Palo Alto, CaliforniaAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT06080061RecruitingPhase 1
Personalized radiation and chemo for lung cancer
This trial is testing a personalized approach to giving radiation and chemotherapy together for lung cancer. It aims to make treatment more effective by tailoring the radiation schedule to each person.
Palo Alto, CaliforniaAges 18 years+ - NCT05997615RecruitingPhase 1
Study of VIR-5500 for advanced prostate cancer
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT05833360Recruiting
Blood test study to match cancer patients to treatment
This study collects a small amount of your blood to analyze cancer signals and sort patients by cancer “size and stage.” The goal is to see whether this blood-based information can help guide cancer care more accurately.
Palo Alto, CaliforniaAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Palo Alto, CaliforniaAges 18 years+ - NCT06646627RecruitingPhase 1
B7-H3 car t cells for platinum-resistant ovarian cancer
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Palo Alto, CaliforniaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Palo Alto, CaliforniaAges 18 years+ - NCT03422198RecruitingPhase 3
Short course vaginal radiation after hysterectomy
This trial tests a short course of targeted vaginal radiation (brachytherapy) after surgery for certain early endometrial cancer. It may help prevent the cancer from coming back in the vaginal area after the uterus has been removed.
Palo Alto, CaliforniaAges Any age - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Palo Alto, CaliforniaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Palo Alto, CaliforniaAges 1 year+ - NCT05406167Recruiting
Tracking quality of life during radiotherapy with a new system
This study collects information about how you feel and how treatment is delivered while you receive radiotherapy using the RefleXion Medical radiotherapy system. It may help doctors improve care and better understand what affects quality of life during treatment.
Palo Alto, CaliforniaAges Any age - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Palo Alto, CaliforniaAges 18–100 - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Palo Alto, CaliforniaAges 18 years+ - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Palo Alto, CaliforniaAges 18–130
Hear when a new Cancer trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting cancer studies listed above.
- Stanford University · 8 studies
- Stanford Cancer Center · 4 studies
- VA Palo Alto Health Care System · 3 studies
- Research Site · 2 studies
- Stanford Cancer Institute · 2 studies
- Stanford Health Care · 2 studies
- Exai Bio Inc.
- Investigational Site Number: 403
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in California.
Common questions
- Are there cancer clinical trials near San Francisco?
- Yes. We're currently tracking 483 recruiting cancer studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.